中国医药
中國醫藥
중국의약
CHINA MEDICINE
2014年
6期
822-825
,共4页
胆汁反流性胃炎%铝碳酸镁%Meta分析%胆汁反流消失率
膽汁反流性胃炎%鋁碳痠鎂%Meta分析%膽汁反流消失率
담즙반류성위염%려탄산미%Meta분석%담즙반류소실솔
Bile reflux gastritis%Hydrotalcite%Meta-analysis%Bile reflux disappear rate
目的 评价铝碳酸镁(商品名:达喜)治疗胆汁反流性胃炎的疗效.方法 采用Cochrane系统评价的方法,检索Medline、康健循证医学知识仓库西文生物医学文献数据库、中国生物医学文献数据库(CBM disk)、维普信息数据库、中国医院数字图书馆、万方医学文献数据库,评价纳入研究的方法学质量,提取有效数据.对照组为对症支持治疗;研究组采用对症支持治疗联合铝碳酸镁1.0g,3次/d,餐后嚼碎服.采用RevMan4.2软件进行Meta分析.结果 共纳入11项随机临床对照研究(770例患者).Meta分析结果显示:研究组与对照组相比,治疗胆汁反流性胃炎临床症状有效率差异有统计学意义,合并效应量比值比为 6.18(95％置信区间:3.89 ～9.81),Z值为7.72,P＜0.01;胆汁反流消失率差异有统计学意义,合并效应量比值比为4.81(95％置信区间:3.25 ～7.12),Z值为7.85,P＜0.01;发表偏倚分析显示散点多集中分布在图形左侧,明显不对称,存在发表偏倚.结论 本研究结果提示目前研究不支持铝碳酸镁治疗胆汁反流性胃炎临床症状有效率及胆汁反流消失率高于非铝碳酸镁治疗者,有必要补充高质量的文献后重新进行Meta分析,进一步评价,急需开展高质量的多中心、大样本、前瞻性、随机、双盲临床试验.
目的 評價鋁碳痠鎂(商品名:達喜)治療膽汁反流性胃炎的療效.方法 採用Cochrane繫統評價的方法,檢索Medline、康健循證醫學知識倉庫西文生物醫學文獻數據庫、中國生物醫學文獻數據庫(CBM disk)、維普信息數據庫、中國醫院數字圖書館、萬方醫學文獻數據庫,評價納入研究的方法學質量,提取有效數據.對照組為對癥支持治療;研究組採用對癥支持治療聯閤鋁碳痠鎂1.0g,3次/d,餐後嚼碎服.採用RevMan4.2軟件進行Meta分析.結果 共納入11項隨機臨床對照研究(770例患者).Meta分析結果顯示:研究組與對照組相比,治療膽汁反流性胃炎臨床癥狀有效率差異有統計學意義,閤併效應量比值比為 6.18(95％置信區間:3.89 ～9.81),Z值為7.72,P＜0.01;膽汁反流消失率差異有統計學意義,閤併效應量比值比為4.81(95％置信區間:3.25 ～7.12),Z值為7.85,P＜0.01;髮錶偏倚分析顯示散點多集中分佈在圖形左側,明顯不對稱,存在髮錶偏倚.結論 本研究結果提示目前研究不支持鋁碳痠鎂治療膽汁反流性胃炎臨床癥狀有效率及膽汁反流消失率高于非鋁碳痠鎂治療者,有必要補充高質量的文獻後重新進行Meta分析,進一步評價,急需開展高質量的多中心、大樣本、前瞻性、隨機、雙盲臨床試驗.
목적 평개려탄산미(상품명:체희)치료담즙반류성위염적료효.방법 채용Cochrane계통평개적방법,검색Medline、강건순증의학지식창고서문생물의학문헌수거고、중국생물의학문헌수거고(CBM disk)、유보신식수거고、중국의원수자도서관、만방의학문헌수거고,평개납입연구적방법학질량,제취유효수거.대조조위대증지지치료;연구조채용대증지지치료연합려탄산미1.0g,3차/d,찬후작쇄복.채용RevMan4.2연건진행Meta분석.결과 공납입11항수궤림상대조연구(770례환자).Meta분석결과현시:연구조여대조조상비,치료담즙반류성위염림상증상유효솔차이유통계학의의,합병효응량비치비위 6.18(95％치신구간:3.89 ～9.81),Z치위7.72,P＜0.01;담즙반류소실솔차이유통계학의의,합병효응량비치비위4.81(95％치신구간:3.25 ～7.12),Z치위7.85,P＜0.01;발표편의분석현시산점다집중분포재도형좌측,명현불대칭,존재발표편의.결론 본연구결과제시목전연구불지지려탄산미치료담즙반류성위염림상증상유효솔급담즙반류소실솔고우비려탄산미치료자,유필요보충고질량적문헌후중신진행Meta분석,진일보평개,급수개전고질량적다중심、대양본、전첨성、수궤、쌍맹림상시험.
Objective To evaluate the efficacy of the hydrotalcite treating bile reflux gastritis.Methods Data from medline,Health knowledge of evidence based medicine warehouse Western biomedical literature database,Wanfang database,CBM disk,VIP information database and china hospital digital library were searched and the references of related studies were checked.The textbooks and meeting reports related to hydrotalcite were manually searched.The quality of included studies was evaluated.Data was extracted into a specially designed extraction form.Control group adopted symptomatic and supportive treatment; study group had symptomatic and supportive treatment combined with hydrotalcite.The Cochrane collaboration's RevMan4.2 software was used for data analysis.Results Eleven randomly controlled clinical studies involving 770 patients were included.The pooled results showed that there were significant differences of the clinical symptom efficacy and the bile reflux disappear rate of the bile reflux gastritis between the hydrotalcite treatment group and the controlled group(combined odds ratio was 6.18 (95 ％ confidence interval:3.89-9.81) and 4.81 (95 ％ confidence interval:3.25-7.12) respectively.Z value was 7.72 and 7.85 respectively; P value was less than 0.01 and 0.01 respectively) ; analysis of publication bias showed that the inverted funnel plot had two dissymmetrical sides.Conclusions Clinical symptom efficacy and the bile reflux disappear rate of the hydrotalcite treatment are not superior to those of the controlled group in treating bile reflux gastritis.Randomized,prospective,double-blind,multi-center and large-scale samples of clinical trials are needed.
